EA201500196A1 - Инъецируемая композиция - Google Patents

Инъецируемая композиция

Info

Publication number
EA201500196A1
EA201500196A1 EA201500196A EA201500196A EA201500196A1 EA 201500196 A1 EA201500196 A1 EA 201500196A1 EA 201500196 A EA201500196 A EA 201500196A EA 201500196 A EA201500196 A EA 201500196A EA 201500196 A1 EA201500196 A1 EA 201500196A1
Authority
EA
Eurasian Patent Office
Prior art keywords
injectable composition
composition
pla
dmso
situ
Prior art date
Application number
EA201500196A
Other languages
English (en)
Other versions
EA033316B1 (ru
Inventor
Гильермо Франко Родригес
Ибон Гутьерро Адурис
Original Assignee
Лабораториос Фармасеутикос Рови, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201500196(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лабораториос Фармасеутикос Рови, С.А. filed Critical Лабораториос Фармасеутикос Рови, С.А.
Publication of EA201500196A1 publication Critical patent/EA201500196A1/ru
Publication of EA033316B1 publication Critical patent/EA033316B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение представляет собой композицию, пригодную для формирования внутримышечного имплантата с содержанием биоразлагаемого термопластичного полимера молочной кислоты (PLA), диметилсульфоксида (DMSO) и ингибитора ароматазы, необходимый набор для приготовления композиции in situ и ее использования в качестве препарата для лечения рака молочной железы.
EA201500196A 2012-08-03 2013-07-29 Инъецируемая композиция EA033316B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201231271A ES2390439B1 (es) 2012-08-03 2012-08-03 Composición inyectable
PCT/EP2013/065877 WO2014019972A1 (en) 2012-08-03 2013-07-29 Injectable compositions comprising letrozole or anastrozole

Publications (2)

Publication Number Publication Date
EA201500196A1 true EA201500196A1 (ru) 2015-05-29
EA033316B1 EA033316B1 (ru) 2019-09-30

Family

ID=47046938

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500196A EA033316B1 (ru) 2012-08-03 2013-07-29 Инъецируемая композиция

Country Status (31)

Country Link
EP (1) EP2879661B1 (ru)
JP (1) JP6317348B2 (ru)
KR (1) KR101892109B1 (ru)
CN (1) CN104519870B (ru)
AU (1) AU2013298705B2 (ru)
BR (1) BR112015002370B1 (ru)
CA (1) CA2880347C (ru)
CL (1) CL2015000259A1 (ru)
CY (1) CY1125157T1 (ru)
DK (1) DK2879661T3 (ru)
EA (1) EA033316B1 (ru)
ES (2) ES2390439B1 (ru)
HK (1) HK1204551A1 (ru)
HR (1) HRP20220537T1 (ru)
HU (1) HUE058322T2 (ru)
IL (1) IL236981B (ru)
IN (1) IN2015DN01711A (ru)
LT (1) LT2879661T (ru)
MA (1) MA37870B1 (ru)
MX (1) MX362874B (ru)
MY (1) MY194726A (ru)
NZ (1) NZ705558A (ru)
PH (1) PH12015500231A1 (ru)
PL (1) PL2879661T3 (ru)
PT (1) PT2879661T (ru)
RS (1) RS63104B1 (ru)
SG (1) SG11201500793VA (ru)
SI (1) SI2879661T1 (ru)
UA (1) UA113317C2 (ru)
WO (1) WO2014019972A1 (ru)
ZA (1) ZA201501426B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) * 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
HRP20211853T1 (hr) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
KR102319352B1 (ko) 2021-02-03 2021-10-29 바이오메디팜 어업회사법인 주식회사 첨연어의 수컷화 비율을 높이는 비호르몬적 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517673D0 (en) 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
BRPI0720346A2 (pt) 2006-10-05 2014-06-24 Panacea Biotec Ltd Composições de depósito (depot) injetáveis e processo de preparação dessas composições.
AR070033A1 (es) * 2007-11-06 2010-03-10 Panacea Biotec Ltd Composiciones inyectables, sus procesos y usos
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
HRP20211853T1 (hr) * 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
CN103384528B (zh) 2010-11-24 2016-04-13 杜雷科特公司 生物可降解的药物递送组合物

Also Published As

Publication number Publication date
SI2879661T1 (sl) 2022-07-29
PH12015500231B1 (en) 2015-04-06
CA2880347C (en) 2021-05-04
HK1204551A1 (en) 2015-11-27
MY194726A (en) 2022-12-15
IN2015DN01711A (ru) 2015-05-22
CN104519870B (zh) 2017-09-15
SG11201500793VA (en) 2015-02-27
EP2879661A1 (en) 2015-06-10
DK2879661T3 (da) 2022-04-19
PT2879661T (pt) 2022-04-06
AU2013298705B2 (en) 2018-03-08
BR112015002370A2 (pt) 2017-07-04
MX362874B (es) 2019-02-20
JP6317348B2 (ja) 2018-04-25
CN104519870A (zh) 2015-04-15
IL236981A0 (en) 2015-03-31
MA37870A1 (fr) 2016-04-29
KR101892109B1 (ko) 2018-09-28
ZA201501426B (en) 2016-01-27
UA113317C2 (xx) 2017-01-10
EA033316B1 (ru) 2019-09-30
LT2879661T (lt) 2022-04-11
RS63104B1 (sr) 2022-04-29
JP2015523405A (ja) 2015-08-13
EP2879661B1 (en) 2022-01-26
CA2880347A1 (en) 2014-02-06
WO2014019972A1 (en) 2014-02-06
MX2015001513A (es) 2015-04-08
ES2926715T3 (es) 2022-10-27
PL2879661T3 (pl) 2022-05-16
CL2015000259A1 (es) 2015-06-05
IL236981B (en) 2021-12-01
CY1125157T1 (el) 2024-02-16
KR20150040337A (ko) 2015-04-14
AU2013298705A1 (en) 2015-03-12
PH12015500231A1 (en) 2015-04-06
ES2390439A1 (es) 2012-11-13
ES2390439B1 (es) 2013-09-27
NZ705558A (en) 2018-02-23
BR112015002370B1 (pt) 2023-04-25
MA37870B1 (fr) 2017-01-31
HRP20220537T1 (hr) 2022-06-10
HUE058322T2 (hu) 2022-07-28

Similar Documents

Publication Publication Date Title
EA201500196A1 (ru) Инъецируемая композиция
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
UY34472A (es) Derivados modificados de 4-fenil-piridina
NZ729417A (en) Compositions and methods for enhancing healing and regeneration of bone and soft tissue
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
IN2014DN11201A (ru)
GT201700190A (es) Desacetoxitubulisina h y análogos de esta
EP2809364A4 (en) INJECTABLE BIODEGRADABLE BONE CEMENT AND METHOD FOR THE PRODUCTION AND USE THEREOF
CY1120142T1 (el) Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης
BR112017018772A2 (pt) material antiadesão e biomembrana substituta usando tecido descelularizado
CO7240413A2 (es) Composición farmacéutica que comprende fimasartan e hidroclorotiazida
BR112013024951A2 (pt) método de tratamento de tecidos biológicos, membranas ou outras estruturas, e, composição para a coloração de tecidos biológicos, membranas ou outras estruturas
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
CY1119470T1 (el) Γαλακταγωγες συνθεσεις με βαση φωσφατιδυλοσερινη
EA201691493A1 (ru) Замещенные n-арилпиридиноны
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
CY1119871T1 (el) Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων
UY34604A (es) Inhibidores de oxadiazol de la producción de leucotrienos para terapia de combinación
UY34277A (es) Metodo para la eliminación del naftaleno